Works matching IS 1042-8194 AND VI 56 AND IP 9 AND DT 2015

Results: 48
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas.

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 9, p. 2598, doi. 10.3109/10428194.2015.1014363
    By:
    • Kimby, Eva;
    • Östenstad, Björn;
    • Brown, Peter;
    • Hagberg, Hans;
    • Erlanson, Martin;
    • Holte, Harald;
    • Linden, Ola;
    • Johansson, Ann-Sofie;
    • Ahlgren, Tomas;
    • Wader, Karin;
    • Wahlin, Björn Engelbrekt;
    • Delabie, Jan;
    • Sundström, Christer
    Publication type:
    Article
    11
    12

    Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 9, p. 2637, doi. 10.3109/10428194.2015.1012714
    By:
    • Tedeschi, Alessandra;
    • Picardi, Paola;
    • Ferrero, Simone;
    • Benevolo, Giulia;
    • Margiotta Casaluci, Gloria;
    • Varettoni, Marzia;
    • Baratè, Claudia;
    • Motta, Marina;
    • Gini, Guido;
    • Goldaniga, Maria Cecilia;
    • Visco, Carlo;
    • Zaja, Francesco;
    • Belsito Petrizi, Valeria;
    • Ravelli, Erika;
    • Gentile, Massimo;
    • Urbano, Marina Aurora;
    • Franceschetti, Silvia;
    • Ghione, Paola;
    • Orsucci, Lorella;
    • Frustaci, Anna Maria
    Publication type:
    Article
    13
    14
    15

    Dissemination pattern of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue.

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 9, p. 2750, doi. 10.3109/10428194.2015.1010161
    By:
    • Ishii, Yoshimi;
    • Tomita, Naoto;
    • Suzuki, Taisei;
    • Ishiyama, Yasufumi;
    • Kishimoto, Kumiko;
    • Yamamoto, Eri;
    • Koyama, Satoshi;
    • Hattori, Yukako;
    • Nakajima, Yuki;
    • Motohashi, Kenji;
    • Takasaki, Hirotaka;
    • Kawasaki, Rika;
    • Hashimoto, Chizuko;
    • Takemura, Sachiya;
    • Fujimaki, Katsumichi;
    • Fujita, Hiroyuki;
    • Sakai, Rika;
    • Fujisawa, Shin;
    • Motomura, Shigeki;
    • Ishigatsubo, Yoshiaki
    Publication type:
    Article
    16
    17

    A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry.

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 9, p. 2556, doi. 10.3109/10428194.2015.1010078
    By:
    • Gang, Anne O.;
    • Pedersen, Michael;
    • d'Amore, Francesco;
    • Pedersen, Lars M.;
    • Jensen, Bo A.;
    • Jensen, Paw;
    • Møller, Michael B.;
    • Mourits-Andersen, Hans T.;
    • Pedersen, Robert S.;
    • Klausen, Tobias W.;
    • de N. Brown, Peter
    Publication type:
    Article
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27

    Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 9, p. 2569, doi. 10.3109/10428194.2015.1007504
    By:
    • Fayad, Luis;
    • Ansell, Stephen M.;
    • Advani, Ranjana;
    • Coiffier, Bertrand;
    • Stuart, Robert;
    • Bartlett, Nancy L.;
    • Forero-Torres, Andres;
    • Kuliczkowski, Kazimierz;
    • Belada, David;
    • Ng, Edmund;
    • Drachman, Jonathan G.
    Publication type:
    Article
    28
    29
    30
    31
    32

    The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 9, p. 2585, doi. 10.3109/10428194.2015.1004167
    By:
    • O'Connor, Owen A.;
    • Gerecitano, John;
    • Van Deventer, Henrik;
    • Hainsworth, John;
    • Zullo, Kelly M.;
    • Saikali, Khalil;
    • Seroogy, Joseph;
    • Wolff, Andrew;
    • Escandón, Rafael
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47

    Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 9, p. 2543, doi. 10.3109/10428194.2014.1001986
    By:
    • Hexner, Elizabeth O.;
    • Mascarenhas, John;
    • Prchal, Josef;
    • Roboz, Gail J.;
    • Baer, Maria R.;
    • Ritchie, Ellen K.;
    • Leibowitz, David;
    • Demakos, Erin P.;
    • Miller, Crystal;
    • Siuty, James;
    • Kleczko, Jill;
    • Price, Leah;
    • Jeschke, Grace;
    • Weinberg, Rona;
    • Basu, Titiksha;
    • Pahl, Heike L.;
    • Orazi, Attilio;
    • Najfeld, Vesna;
    • Marchioli, Roberto;
    • Goldberg, Judith D.
    Publication type:
    Article
    48

    Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma.

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 9, p. 2592, doi. 10.3109/10428194.2014.1001985
    By:
    • Shiratori, Souichi;
    • Kosugi-Kanaya, Mizuha;
    • Shigematsu, Akio;
    • Kobayashi, Hajime;
    • Yamamoto, Satoshi;
    • Kobayashi, Naoki;
    • Iwasaki, Hiroshi;
    • Mori, Akio;
    • Kunieda, Yasuyuki;
    • Yutaka, Tsutsumi;
    • Kurosawa, Mitsutoshi;
    • Kakinoki, Yasutaka;
    • Endo, Tomoyuki;
    • Kondo, Takeshi;
    • Hashino, Satoshi;
    • Teshima, Takanori
    Publication type:
    Article